Skip to main content Back to Top
Advertisement

10/9/2019

Griseofulvin Oral Presentations

Products Affected - Description

    • Griseofulvin oral tablet, Rising Pharmaceuticals, 500 mg, bottle, 30 count, NDC 64980-0186-03 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 500 mg, bottle, 100 count, NDC 64980-0186-01 - discontinued
    • Griseofulvin oral suspension, Teva, 125 mg/5 mL, 120 mL bottle, 1 count, NDC 00472-0013-04
    • Griseofulvin oral tablet, Amneal, 125 mg, bottle, 100 count, NDC 00115-1724-01
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 125 mg, bottle, 30 count, NDC 64980-0184-03 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 125 mg, bottle, 100 count, NDC 64980-0184-01 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 250 mg, bottle, 30 count, NDC 64980-0185-03 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 250 mg, bottle, 100 count, NDC 64980-0185-01 - discontinued

Reason for the Shortage

    • Amneal did not provide a reason for the shortage.
    • Cipla has griseofulvin suspension available.
    • Rising discontinued griseofulvin products.
    • Sandoz has griseofulvin tablets available.
    • Teva did not provide a reason for the shortage.

Available Products

    • Griseofulvin oral suspension, Cipla USA, 125 mg/5 mL, 120 mL bottle, 1 count, NDC 69097-0361-08
    • Griseofulvin oral tablet, Sandoz, 500 mg, bottle, 100 count, NDC 00781-5515-01

Estimated Resupply Dates

    • Amneal has griseofulvin ultramicrocrystalline 125 mg tablets on back order and the company cannot estimate a release date.
    • Teva has griseofulvin microcrystalline 125 mg/5 mL suspension in 120 mL bottles on intermittent back order and the company is releasing supplies as they become available.

Updated

Updated October 9, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 18, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins